On Jan. 06, Konstantinovsky Irina divested U.S. $2,006,854 in shares of Horizon Therapeutics Public Limited Company. The EVP, Chief HR Off sold 26,844 shares at a price per share of $74.76. The transaction decreased this specific insider’s holdings to 86,499 shares worth around $6.88 million at present.
Another 27,106 shares were sold by Desjardin Michael A., for more than $2,032,950 in total proceeds. The EVP, Technical Operations dumped the shares at a price of $75.00 and the insider now owns almost 114,662 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
That same day, Karnani Vikram sold 30,031 shares. The EVP, Pres, International divested U.S. $2,252,325 in shares of Horizon Therapeutics Public Limited Company at a price per share of $75.00. The transaction decreased this specific insider’s holdings to 111,429 shares worth around $8863062.66 at present.
JP Morgan launched its Horizon Therapeutics Public Limited Company [HZNP] rating to the equivalent of an Overweight and assigned the price target of $110, in a research note dated September 09, 2020. That figure represents around a 27.69% premium from where the company’s shares closed on Friday. Some new analysts also started their coverage, with JP Morgan’s analysts assigning the shares to “an Overweight” rating in a research note to investors issued in early September. Meanwhile, Citigroup had launched its coverage on HZNP with “Buy”, in a research note produced for clients August 27, 2020. In addition, there was a new coverage from Goldman on January 08, 2020. The research firm rated HZNP “a Neutral”.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
Is Horizon Therapeutics Public Limited Company [NASDAQ:HZNP] a Good Buy Right Now?
It should be noted that HZNP technical indicators for short, intermediate as well as long term progress have placed an overall average of 72% as Buy. The average signal changed from 24% Buy in the last week and compares with 24% Buy in the past month. Data from Horizon Therapeutics Public Limited Company’s Trend Spotter indicated that the signals were Strengthening. The stock current average is 2.74 million shares in the past 20 days and the short term average signal indicates a 50% Buy. In the last 50 days, the average trading volume was 2.81 million shares while the medium term average advocated for 50% Buy. The average long-term signal stands at 100% Buy and the 100-day average volume stands at 2.39 million shares.
HZNP Price Performance
On Wall Street, Horizon Therapeutics Public Limited Company [NASDAQ:HZNP] finished Friday’s session down -0.08% at $79.54. The stock went up to $80.58 at the same session while its lowest single day price was $78.0297. In the last five days, it saw a rise of about 8.74%, Horizon Therapeutics Public Limited Company shares gained by almost 8.74% since the beginning of the year. However, the share price has dropped to as low as -8.23% below its one year high. On 01/08/21, the company shares recorded $80.58, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/04/21, the same year at $70.88. The company’s shares have inclined by 119.24% in the past year. The 50-day SMA achieved is $72.61 while the 200-day SMA is $61.76. Volume dropped to 1.8 million from 2.03 million in the previous session.
Horizon Therapeutics Public Limited Company [HZNP] Valuation Measures
Notably, Horizon Therapeutics Public Limited Company [HZNP] stock can be classified as a good candidate in the listing of underestimated low-priced Drug Manufacturers – General companies to purchase soonest possible with the prevailing 12-month PE ratio of 21.72. The measure means the stock is exchanging at a discount as compared to the 24.35x trailing earnings of the industry. It can be helpful for investors to consider historical price-sales ratio, more specifically, a 9.66 PS value ratio is reported for the last one year of reported earnings. That is higher than the industry average of 2.89 which means HZNP serve an attractive investment opportunity compared to its competitors.
HZNP Stock Support And Resistance Levels
On the 24-hour scale, the immediate backing is perceived around 78.19 level, and in case of violation of this particular level, it will cause more drop to 76.83 level. On the upper level, 81.93 is still the key resistance. The stock may increase to the subsequent resistance at 80.74. The Relative Strength Index (RSI) pinned on the 14-day chart is 65.90, implying a neutral technical stance while the MACD stands at 6.17, meaning price will increase in the next trading period. Percent R indicator moved to 7.34%, implying bullish price movement. Stochastic %K at 89.97% suggest selling the stock.
What is the short interest in Horizon Therapeutics Public Limited Company?
Short interest in the Horizon Therapeutics Public Limited Company stock has plunged, decreasing by -2.61 million shares to total 8.91 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 6.3 million, data from Yahoo Finance shows. The increase of 29.29% suggests the stock saw some increased bearish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 4.09% of the overall float for the stock.
Horizon Therapeutics Public Limited Company’s Biggest Shareholders: Who Owns Horizon Therapeutics Public Limited Company [HZNP]?
Filings by The Vanguard Group, Inc. showed that the firm now holds a total of 18,940,305 shares or roughly 8.58% of the outstanding HZNP shares. This means their shares have increased by 1,493,761 from the 18,940,305 the investor reportedly held in its prior 13-F filing. With the conclusion of the purchase, Fidelity Management & Research Co updated stake is worth $1,132,313,252. Details in the latest 13F filings reveal that BlackRock Fund Advisors acquired their 1.74% stake valued at $738,788,374 while Janus Capital Management LLC added theirs at $629,514,116. During the last quarter, BlackRock Fund Advisors raised 179,606 of its shares in Horizon Therapeutics Public Limited Company while Janus Capital Management LLC bought 580,629 shares. The Renaissance Technologies LLC’s holdings currently number 8,780,875 shares at $698430797.5. According to the firm’s last 13F report, Avoro Capital Advisor LLC shares in the company at filing stood at 7,650,000 shares, roughly $538,789,500.
HZNP Earnings Forecast For The Current Quarter
Horizon Therapeutics Public Limited Company [HZNP] is expected to report strong earnings results for the quarter ending on Dec 2020. Consensus estimates give the company expected revenues of $678.3M and an earnings per share of $1.02 for Dec 2020. Looking further ahead, the company is expected to report revenue of $478.16M at an EPS of $0.53 for Mar 2021. The estimates represent upside of 27.30% and 18.91% in the company’s revenue and earnings per share, respectively, on a year-on-year basis.
HZNP Earnings Estimates For The Current Year
For the financial year, Horizon Therapeutics Public Limited Company [NASDAQ:HZNP] is expected to bring in revenue of $2.13B. The returns are nearly $830.0 million higher than the company’s actual revenue recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at 3.61, higher than that of FY19 by $1.67. Estimates put this year’s earnings growth at 86.10%, 18.80% for the next, and at an annual 30.20% over the next 5-year period. As for sales, forecasts are for an increase of 64.10% in the current fiscal year and a further 27.30% over the following year.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
What are analyst thoughts on Horizon Therapeutics Public Limited Company?
Looking forward to the Horizon Therapeutics Public Limited Company share price prediction, we can see that analysts, surveyed by FactSet, offer the mean price target for Horizon Therapeutics Public Limited Company stock at $108.00 within the next 12 months, which represents almost 26.35 per cent growth from its previous closing price of $79.54. The highest analysts’ target for Horizon Therapeutics Public Limited Company stock projections is $123.00 and the lowest one is $81.00. Still, 11 analysts sharing their consensus rating for HZNP stock in 2021 agree that it is a Buy.
